Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech firesales -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (860)	12/19/2005 1:48:23 AM
From: tnsaf	Read Replies (1) \| Respond to of 3661

Drbio45 claims that "Myogen also eliminated people with connective tissue disease from this trial. Those people don't do as well as the rest of the population with the endothelin antagonists." but I don't see that in the description of the trial at www.clinicaltrials.gov. clinicaltrials.gov Exclusion Criteria: Portopulmonary hypertension; Subjects with PAH due to or associated with coronary artery disease, left heart disease, interstitial lung disease, chronic obstructive pulmonary disease, veno-occlusive disease, chronic thromboembolic disease, or sleep apnea; Bosentan (Tracleer®), sildenafil (Viagra®), or chronic prostanoid therapy within 4 weeks of screening; Serum ALT or AST lab value that is greater than 1.5 times the upper limit of normal; Contraindication to treatment with an endothelin receptor antagonist; Subject with cardiovascular, hepatic, renal, hematologic, gastrointestinal, immunologic, endocrine, metabolic, or central nervous system disease that may adversely affect the safety of the subject; Participation in a clinical study involving another investigational drug within 4 weeks of screening. Exclusion criteria for ENCY's trial (from encysive.com 1. Portal hypertension or chronic liver disease. 2. ALT or AST levels greater than 1.5 times the upper limit of normal at the Screening Visit 3. Contraindication to treatment with an endothelin receptor antagonist 4. Recent history of abusing alcohol or illicit drugs 5. Chronic renal insufficiency 6. Pregnant or breastfeeding 7. Atrial septostomy within 30 days before study entry 8. Previous failure on bosentan because of safety concerns or the lack of clinical response